- Pfizer will study the effectiveness of its vaccine in young people aged 6 months to 11 years.
- The messenger RNA vaccines, Pfizer and Moderna, protect 90% against infection after the injection of two doses and 80% after a single dose.
Are we going to vaccinate the children? If the question is not yet decided, the laboratories Pfizer and BioNTech ensure that their vaccine is of maximum effectiveness in adolescents. On Wednesday, they announced the results of phase 3 clinical trials conducted on 2,260 young Americans between the ages of 12 and 15, according to which their serum has “demonstrated 100% efficacy and robust antibody responses”, They wrote in a statement.
Studies on children aged 6 months to 11 years in progress
The two groups have indicated that they will now submit this data to various regulatory authorities around the world. “hoping to start vaccinating this age group before the start of the next school year.” For now, vaccination is only authorized for people over 16 years of age in the United States and the European Union.
The group has also announced that it is conducting trials to study the effects of vaccination on younger children. A first group of children aged 5 to 11 received the first doses of the vaccine last week. A younger cohort of children aged 2 to 5 is expected to receive their first dose next week as part of the study which will also cover children aged 6 months to 2 years.
Pfizer and Moderna protect 90% against infections
In addition, vaccines that use messenger RNA technology, such as Pfizer and the one developed by Moderna, would drastically reduce the risk of infection in addition to preventing severe forms of Covid-19. According to a study presented on Monday March 29 by Centers of Disease Control and PreventionAccording to US health authorities, the number of people infected with SARS-CoV-2 drops dramatically in people who are vaccinated, even after a single dose is injected.
To do this, they observed 3,950 volunteers, never contaminated, working in the health sector or in direct contact with the population, between December 14 and March 13. Of these, 2,479 received both injections of Pfizer or Moderna sera while 477 received only one dose and the rest were not vaccinated. Every week, they all performed an RT-PCR test, regardless of their symptomatic status.
The results showed that vaccines reduce the risk of infection by 90% after two doses and by 80% after a single injection. In the fully vaccinated population, ie fifteen days after the second dose, there were 0.04 infections per 1000 people. In the partially vaccinated population, that is to say fifteen days after the first dose, there was 0.19 infections per 1000 people. Finally, in the unvaccinated population, there were 1.38 infections per 1,000 people.
Get the latest news delivered to your inbox
Follow us on social media networks